These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 23259529)
1. Angiotensin II type 1 and type 2 receptor expression in circulating monocytes of diabetic and hypercholesterolemic patients over 3-month rosuvastatin treatment. Marino F; Maresca AM; Cosentino M; Castiglioni L; Rasini E; Mongiardi C; Maio RC; Legnaro M; Schembri L; Dentali F; Grandi AM; Guasti L Cardiovasc Diabetol; 2012 Dec; 11():153. PubMed ID: 23259529 [TBL] [Abstract][Full Text] [Related]
2. Effect of statins on soluble CD40 ligand in hypercholesterolemic Type 2 diabetic patients. Santini E; Madec S; Corretti V; Ferrannini E; Solini A J Endocrinol Invest; 2008 Jul; 31(7):660-5. PubMed ID: 18787388 [TBL] [Abstract][Full Text] [Related]
3. Effects of statins on vascular endothelial function in hypercholesterolemic patients with type 2 diabetes mellitus: fluvastatin vs. rosuvastatin. Tomizawa A; Hattori Y; Suzuki K; Okayasu T; Kase H; Satoh H; Kasai K Int J Cardiol; 2010 Sep; 144(1):108-9. PubMed ID: 19174316 [No Abstract] [Full Text] [Related]
4. Cardiac hypertrophy during hypercholesterolemia and its amelioration with rosuvastatin and amlodipine. Kang BY; Wang W; Palade P; Sharma SG; Mehta JL J Cardiovasc Pharmacol; 2009 Oct; 54(4):327-34. PubMed ID: 19687748 [TBL] [Abstract][Full Text] [Related]
5. Usefulness of aggressive lipid-lowering therapy with rosuvastatin in hypercholesterolemic patients with concomitant type 2 diabetes. Mori Y; Kuriyama G; Tanaka T; Tajima N Endocrine; 2009 Dec; 36(3):412-8. PubMed ID: 19834827 [No Abstract] [Full Text] [Related]
7. A review of the efficacy of rosuvastatin in patients with type 2 diabetes. Tuomilehto J; Leiter LA; Kallend D Int J Clin Pract Suppl; 2004 Oct; (143):30-40. PubMed ID: 16035394 [TBL] [Abstract][Full Text] [Related]
8. Rosuvastatin treatment improves arterial stiffness with lowering blood pressure in healthy hypercholesterolemic patients. Oh PC; Han SH; Koh KK; Lee K; Seo JG; Suh SY; Ahn T; Choi IS; Shin EK Int J Cardiol; 2014 Oct; 176(3):1284-7. PubMed ID: 25135328 [No Abstract] [Full Text] [Related]
9. Rosuvastatin increased serum osteocalcin levels independent of its serum cholesterol-lowering effect in patients with type 2 diabetes and hypercholesterolemia. Kanazawa I; Yamaguchi T; Yamauchi M; Sugimoto T Intern Med; 2009; 48(21):1869-73. PubMed ID: 19881236 [TBL] [Abstract][Full Text] [Related]
10. Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients. Koh KK; Quon MJ; Sakuma I; Han SH; Choi H; Lee K; Shin EK Int J Cardiol; 2013 Jun; 166(2):509-15. PubMed ID: 22204857 [TBL] [Abstract][Full Text] [Related]
11. Rosuvastatin therapy does not affect serum MMP-13 or TIMP-1 levels in hypercholesterolemic patients. Cevik C; Nugent K; Meyerrose G; Otahbachi M; Izgi C; Lyte M; Fish RD Tex Heart Inst J; 2011; 38(3):229-33. PubMed ID: 21720458 [TBL] [Abstract][Full Text] [Related]
12. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Catapano AL; Davidson MH; Ballantyne CM; Brady WE; Gazzara RA; Tomassini JE; Tershakovec AM Curr Med Res Opin; 2006 Oct; 22(10):2041-53. PubMed ID: 17022864 [TBL] [Abstract][Full Text] [Related]
13. Rosuvastatin attenuates atherosclerosis in rats via activation of scavenger receptor class B type I. Li Y; Wang Q; Zhou J; Xu Q; Chu X; Sun T; Liu X; Cai S Eur J Pharmacol; 2014 Jan; 723():23-8. PubMed ID: 24333476 [TBL] [Abstract][Full Text] [Related]
14. Evolution and involution of atherosclerosis and its relationship with vascular reactivity in hypercholesterolemic rabbits. Ozaki MR; de Almeida EA Exp Toxicol Pathol; 2013 Mar; 65(3):297-304. PubMed ID: 22024507 [TBL] [Abstract][Full Text] [Related]
15. Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia. Qu HY; Xiao YW; Jiang GH; Wang ZY; Zhang Y; Zhang M Pharm Res; 2009 Apr; 26(4):958-64. PubMed ID: 19082693 [TBL] [Abstract][Full Text] [Related]
16. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Olsson AG; McTaggart F; Raza A Cardiovasc Drug Rev; 2002; 20(4):303-28. PubMed ID: 12481202 [TBL] [Abstract][Full Text] [Related]
17. Rosuvastatin prevents myocardial necrosis in an experimental model of acute myocardial infarction. Dourado PM; Tsutsui JM; Landim MB; Casella Filho A; Galvao TF; Aiello VD; Mathias W; da Luz PL; Chagas AC Braz J Med Biol Res; 2011 May; 44(5):469-76. PubMed ID: 21445530 [TBL] [Abstract][Full Text] [Related]
18. The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation. Calkin AC; Giunti S; Sheehy KJ; Chew C; Boolell V; Rajaram YS; Cooper ME; Jandeleit-Dahm KA Diabetologia; 2008 Sep; 51(9):1731-40. PubMed ID: 18594792 [TBL] [Abstract][Full Text] [Related]
19. Soybean glycinin improves HDL-C and suppresses the effects of rosuvastatin on hypercholesterolemic rats. Fassini PG; Noda RW; Ferreira ES; Silva MA; Neves VA; Demonte A Lipids Health Dis; 2011 Sep; 10():165. PubMed ID: 21936891 [TBL] [Abstract][Full Text] [Related]
20. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies. Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]